M&A In Medical Devices: A More Robust Climate? Yes & No
Over the last three years, deal values in medical device M&A have hit all time highs, with more big deals done than ever before. Still, even with deal values soaring, device M&A remains a small-stakes game. IN VIVO looks at dealmaking in medtech by therapeutic and industry segments.
You may also be interested in...
A look back at the biggest devices stories of the decade, in capsule form.
Notwithstanding an occasional blip, the environment for medical device companies has never been stronger, with robust technology development, company creation rewarded with high levels of private and venture investment, and strong M&A activity all supporting a business model that was born out of the doldrums that device companies found themselves in a decade ago. Still, there are pressures that are straining the current model and raising legitimate concerns, including physician conflict-of-interest charges; regulatory pathways that are trickier and a climate of evidence-based medicine that leads to longer, more expensive trials; and a robust M&A environment that is sustainable only if a next-generation of acquiring companies steps up. Part one of a two-part series.
Brief summaries of recent medtech market and industry developments. This month we cover secondary buyers as an exit strategy for Boston Scientific and others; a review of medtech dealmaking in the first quarter of 2008, and US markets for patient monitoring products.